• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Lena Winestone: Disparities in Outcomes in Children With AML Based on Neighborhood Characteristics

Video

Children with acute myeloid leukemia (AML) who come from neighborhoods with lower income have poorer outcomes and may have access to care issues, said Lena Winestone, MD, assistant professor of pediatrics at the University of California, San Francisco.

Children with acute myeloid leukemia (AML) who come from neighborhoods with lower income have poorer outcomes and may have access to care issues, said Lena Winestone, MD, assistant professor of pediatrics at the University of California, San Francisco.

Transcript

What have you found regarding how neighborhoods, specifically if they are those with low income and low education, impact survival in children with cancer?

So, we found that children with acute myeloid leukemia, a type of leukemia that affects children, have an increased risk of mortality if they come from a low-income or high-poverty neighborhood. In particular we looked at that and broke it down in several different ways. We looked at the risk of relapse and found that there was an increased risk of relapse among those patients. And in addition, we found that they had a higher risk of toxicity that led to mortality among that patient population.

Finally, we looked at early mortality as a marker, potentially, of access to care, and found that low-income patients also have a substantial increased risk of early mortality or death during the first course of chemotherapy, suggesting that a component of what’s going on may be related to access.

Related Videos
Debra Boyer, MD, MHPE, ATSF.
Video 2 - "Payer Needs and Strategies for Evaluating and Covering PDTs"
Video 1 - "Differentiating PDTs from Wellness Apps and Evaluating Efficacy"
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Plasminogen is vital in the body's coagulation process and breaking down clots | image credit: peterschreiber.media - stock.adobe.com
ISPOR 2024 Recap
Chris Pagnani, MD, PC
Video 4 - "Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer"
Video 3 - "The Role of Oral SERDs in ER+/HER2- Metastatic Breast Cancer"
Screenshot of Stephen Freedland, MD, during a video interview
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.